Pirlindole in the treatment of depression and fibromyalgia syndrome.

摘要: Depression and fibromyalgia syndrome are debilitating chronic conditions that impose a significant burden on individuals, families society. Both depression have many overlapping symptoms, antidepressants of several classes among recommended treatment options for patients with syndrome. Pirlindole is selective reversible inhibitor monoamine oxidase (MAO) subtype A (MAO-A) approved in some European non-European countries the depression. The antidepressant efficacy safety pirlindole been demonstrated number placebo- active comparator-controlled studies supported by years clinical experience drug's also demonstrated, more recently, has favourable tolerability profile, no deleterious effect cardiovascular dynamics. sensorimotor performance relevant to driving motor vehicle similar placebo, as appears an activating rather than sedating profile. Because its specific inhibition MAO-A relatively short elimination half-life, tyramine or 'cheese' likely after short- long-term administration. available evidence supports safe effective option management